Sat, Aug 23, 2014, 10:15 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Akorn, Inc. Message Board

theguywho2 7 posts  |  Last Activity: Aug 7, 2014 10:29 AM Member since: Mar 23, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The interim analysis was performed on data from the first 50% of patients
    who completed the study. The purpose of the interim analysis was to allow for a
    sample size adjustment if necessary to maintain appropriate statistical power to
    detect a treatment effect between Clonidine Topical Gel and placebo.
    BDSI views the outcome of the analysis as very encouraging. As a result
    of the interim analysis, a total of approximately 80 additional patients will be
    added to the ongoing trial in an effort to maintain 90% percent power to detect
    a statistically significant difference between Clonidine Topical Gel and placebo.
    The analysis was executed by an independent biostatistician.
    "We are encouraged by the outcome of the interim analysis," stated Dr. Andrew
    Finn, Executive Vice President of Product Development at BDSI. "The additional patients
    not only allow us to maintain the probability of ultimately meeting the study's
    endpoints, but given that the initial study enrollment was about three months ahead
    of schedule, we still anticipate having top-line results by the end of the first
    quarter of 2015. In addition, the expanded sample size will provide an adequate
    number of subjects to complete the required long-term safety study that will be
    part of our NDA package. Also part of the NDA will be a second pivotal trial that
    we anticipate starting in early 2015."
    "The outcome of the interim analysis is significant because it utilized actual
    study data to make a sample size adjustment to maintain the probability of a successful
    outcome," said Dr. Mark A. Sirgo, President and Chief Executive Officer. "Based
    on this information we will continue to progress other aspects of the clinical development
    program necessary for the NDA."

  • Is anyone following this company ?

  • theguywho2 by theguywho2 Jun 27, 2014 12:28 PM Flag

    Apparently shorts are driven by a greater greed even though it appears now that failure is not eminent. With a pending squeeze pending, it stands to reason why they just won't let it go. Sooner or later there will be an event to shake up this log jam.

    Sentiment: Hold

  • theguywho2 by theguywho2 Jun 25, 2014 5:07 PM Flag

    The company now has a fully-functional, roll-to-roll pilot production line comprised of a plating line at the company's Texas facility, and printing, final testing and packaging at the Kodak facility, a state-of-the-art manufacturing and testing facility within the Eastman Business Park in Rochester, New York. UniPixel and Kodak have begun conducting roll-to-roll pilot manufacturing and yield studies on the overall process, as well as technology transfer of the modified process to production plating assets in the Kodak facility.

  • theguywho2 by theguywho2 Jun 10, 2014 3:13 PM Flag

    Houston we don't have a problem !

  • Reply to

    18$ price target,

    by espo1900 Jun 9, 2014 12:25 PM
    theguywho2 theguywho2 Jun 9, 2014 12:55 PM Flag

    Not gonna happen.

  • theguywho2 by theguywho2 Jun 4, 2014 3:45 PM Flag

    The short move was from 37 to 5. That's it, what are you waiting for?
    Another dollar, dollar and a half? Not gonna happen. There is a lot of shares to cover out there. The ones
    who wait the longest, will give back most of the profits. Buying back the borrowed stock is inevitable. Better get crackin' ! Just saying'

37.74+0.19(+0.51%)Aug 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.